吉西他滨
纳米载体
医学
纳米医学
胰腺癌
胰腺导管腺癌
药品
疾病
癌症
常用化疗药物
肿瘤科
内科学
药理学
癌症研究
纳米技术
材料科学
纳米颗粒
作者
Pablo Javier Romano Redruello,Gloria Perazzoli,Ana Cepero,Francisco Palacios Quiñonero,Cristina Mesas,Kevin Doello,Antonio Jesús Láinez Ramos-Bossini,Mario Rivera-Izquierdo,Consolación Melguizo,Jose Prados
出处
期刊:Current Drug Targets
[Bentham Science]
日期:2020-11-30
卷期号:21 (15): 1580-1592
被引量:2
标识
DOI:10.2174/1389450121666200703195229
摘要
Pancreatic ductal adenocarcinoma (PDA) has one of the worst prognosis and higher mortality among most cancers. The diagnosis of PDA is frequently delayed due to a lack of specific biomarkers, and the efficacy of current chemotherapeutic drugs is limited. Moreover, chemotherapy is generally applied in advanced stages, where metastatic spread has already occurred. Nanotechnologybased systems are allowing to advance in the diagnosis and treatment of PDA. New nanoformulations have shown to improve the activity of conventional chemotherapeutic agents, such as gemcitabine, and new antitumor drugs, protecting them from degradation, improving their selectivity, solubility and bioavailability, and reducing their side effects. Moreover, the design of nanocarriers represents a new way to overcome drug resistance, which requires a comprehensive understanding of the tumor microenvironment of PDA. This article reviews the current perspectives, based on nanomedicine, to address the limitations of pancreatic cancer treatment, and the futures lines of research to progress in the control of this disease.
科研通智能强力驱动
Strongly Powered by AbleSci AI